BG100236A - Sheared keratiocytic growth factor (kgf) of increased biological activity - Google Patents

Sheared keratiocytic growth factor (kgf) of increased biological activity

Info

Publication number
BG100236A
BG100236A BG100236A BG10023695A BG100236A BG 100236 A BG100236 A BG 100236A BG 100236 A BG100236 A BG 100236A BG 10023695 A BG10023695 A BG 10023695A BG 100236 A BG100236 A BG 100236A
Authority
BG
Bulgaria
Prior art keywords
kgfdesl
growth factor
relates
keratiocytic
sheared
Prior art date
Application number
BG100236A
Other languages
Bulgarian (bg)
English (en)
Inventor
Denis Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of BG100236A publication Critical patent/BG100236A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
BG100236A 1993-06-29 1995-12-20 Sheared keratiocytic growth factor (kgf) of increased biological activity BG100236A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (1)

Publication Number Publication Date
BG100236A true BG100236A (en) 1996-07-31

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100236A BG100236A (en) 1993-06-29 1995-12-20 Sheared keratiocytic growth factor (kgf) of increased biological activity

Country Status (25)

Country Link
US (7) US5677278A (xx)
EP (2) EP1493812A3 (xx)
JP (4) JP3570516B2 (xx)
KR (1) KR960703433A (xx)
CN (1) CN1129955A (xx)
AT (1) ATE278777T1 (xx)
AU (1) AU681405B2 (xx)
BG (1) BG100236A (xx)
BR (1) BR9407035A (xx)
CA (1) CA2166278A1 (xx)
CZ (1) CZ343795A3 (xx)
DE (2) DE122006000005I2 (xx)
DK (1) DK0706563T3 (xx)
ES (1) ES2227527T3 (xx)
FI (1) FI956203A (xx)
FR (1) FR06C0004I2 (xx)
HU (1) HUT73453A (xx)
LU (1) LU91215I2 (xx)
NL (1) NL300217I2 (xx)
NO (1) NO955189L (xx)
NZ (1) NZ266622A (xx)
PL (1) PL312257A1 (xx)
PT (1) PT706563E (xx)
SK (1) SK153295A3 (xx)
WO (1) WO1995001434A1 (xx)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
WO1995001434A1 (en) * 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
CN1168678A (zh) * 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
DE69530599T2 (de) * 1994-10-13 2003-11-13 Amgen Inc., Thousand Oaks Methode zur reinigung von keratinocyten-wachstumsfaktoren
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
PT1486565E (pt) * 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JP2002513294A (ja) * 1997-06-19 2002-05-08 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2320515A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
AU2002236477A1 (en) 2000-11-21 2002-06-03 The Texas A & M University System Fgf-affinity chromatography
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
PL374269A1 (en) * 2001-08-21 2005-10-03 Chiron Corporation Kgf polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
JP5201992B2 (ja) * 2004-12-15 2013-06-05 バイオビトラム・アクテイエボラーグ(パブリツク) ケラチノサイト増殖因子の治療用製剤
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CN117858717A (zh) 2021-08-30 2024-04-09 联合化学实验室有限公司 用于治疗炎症性疾病的蛋白质组合物
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
WO1995001434A1 (en) 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
CN1168678A (zh) 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs

Also Published As

Publication number Publication date
CN1129955A (zh) 1996-08-28
FI956203A (fi) 1996-02-07
US5677278A (en) 1997-10-14
JP2009062396A (ja) 2009-03-26
JPH09500267A (ja) 1997-01-14
AU681405B2 (en) 1997-08-28
LU91215I2 (en) 2006-03-27
BR9407035A (pt) 1996-03-12
JP4662569B2 (ja) 2011-03-30
US20090093400A1 (en) 2009-04-09
NO955189D0 (no) 1995-12-20
CA2166278A1 (en) 1995-01-12
DE69434053D1 (de) 2005-01-20
HU9503857D0 (en) 1996-02-28
FI956203A0 (fi) 1995-12-22
JP2006075173A (ja) 2006-03-23
JP3570516B2 (ja) 2004-09-29
EP0706563A1 (en) 1996-04-17
AU6820894A (en) 1995-01-24
NL300217I1 (nl) 2006-04-03
NO955189L (no) 1995-12-20
FR06C0004I1 (xx) 2006-03-10
PT706563E (pt) 2005-01-31
US5773586A (en) 1998-06-30
EP1493812A3 (en) 2006-02-08
US6677301B1 (en) 2004-01-13
DE122006000005I1 (de) 2006-08-10
EP1493812A2 (en) 2005-01-05
DK0706563T3 (da) 2005-01-31
FR06C0004I2 (fr) 2006-12-29
WO1995001434A1 (en) 1995-01-12
DE122006000005I2 (de) 2006-11-23
EP0706563B1 (en) 2004-10-06
KR960703433A (ko) 1996-08-17
PL312257A1 (en) 1996-04-01
US5843883A (en) 1998-12-01
DE69434053T2 (de) 2006-02-23
NL300217I2 (nl) 2006-05-01
NZ266622A (en) 1997-10-24
US6074848A (en) 2000-06-13
JP2004166709A (ja) 2004-06-17
HUT73453A (en) 1996-08-28
CZ343795A3 (en) 1996-07-17
ES2227527T3 (es) 2005-04-01
SK153295A3 (en) 1996-11-06
ATE278777T1 (de) 2004-10-15
US5863767A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
BG100236A (en) Sheared keratiocytic growth factor (kgf) of increased biological activity
DE3650055T2 (de) Fibroblast-wachstumsfaktor.
AU704515C (en) Novel protein and process for producing the same
DE3584120D1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
CA2223433A1 (en) Ob protein compositions and methods
WO1991004316A3 (en) Ciliary neurotrophic factor
JPH02504279A (ja) インスリン様成長因子1(igf‐1)または因子2(igf‐2)の類縁ペプチド
AU3368497A (en) Human dnase i hyperactive variants
CN101534847A (zh) 修饰型促红细胞生成素
JPS62501609A (ja) ヒト成長ホルモンの製造方法
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
WO1993019084A1 (en) Refolding and purification of insulin-like growth factor i
DE69029415T2 (de) Osteogenische Wachstumfaktoren, die aus sich regenerierendem Knochenmark identifiziert werden
HRP940432B1 (en) Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
EP0241136A3 (en) Human class 1 heparin-binding growth factor
AU7430500A (en) Monomeric analogues of human insulin
DE69730967D1 (en) Human dnase ii
ZA961419B (en) Human DNase I variants.
WO1991006560A1 (de) Quervernetzte tumor-nekrose-faktoren
GR3031254T3 (en) Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same
MX9800686A (es) Nueva proteina hmw humana mp52s.
JPS63316798A (ja) 新規なペプチド及びこれを有効成分とする創傷治療剤
RU96104372A (ru) НОВЫЙ ФАКТОР РОСТА / ДИФФЕРЕНЦИАЦИИ TGF-β--СЕМЕЙСТВА
MX9504057A (es) Proteina que tiene actividad tpo.
RU95122751A (ru) Укороченный кератиноцитарный фактор роста с повышенной биологической активностью